Monopar Therapeutics Inc
$ 56.22
-2.56%
17 Apr - close price
- Market Cap 386,136,000 USD
- Current Price $ 56.22
- High / Low $ 59.43 / 56.22
- Stock P/E N/A
- Book Value 20.59
- EPS -1.85
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.10 %
- ROE -0.14 %
- 52 Week High 105.00
- 52 Week Low 28.40
About
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to developing proprietary therapies to improve clinical outcomes for cancer patients in the United States. The company is headquartered in Wilmette, Illinois.
Analyst Target Price
$112.79
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-30 | 2025-11-10 | 2025-08-12 | 2025-05-07 | 2025-03-26 | 2024-11-07 | 2024-08-09 | 2024-05-09 | 2024-03-28 | 2023-11-09 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.61 | -0.48 | -0.35 | -0.38 | -2.75 | -0.37 | -0.5 | -0.1 | -0.12 | -0.14 | -0.16 | -0.19 |
| Estimated EPS | -0.5123 | -0.3989 | -0.09 | -0.5667 | -0.42 | -0.48 | -0.47 | -0.12 | -0.15 | -0.17 | -0.18 | -0.22 |
| Surprise | -0.0977 | -0.0811 | -0.26 | 0.1867 | -2.33 | 0.11 | -0.03 | 0.02 | 0.03 | 0.03 | 0.02 | 0.03 |
| Surprise Percentage | -19.0709% | -20.3309% | -288.8889% | 32.9451% | -554.7619% | 22.9167% | -6.383% | 16.6667% | 20% | 17.6471% | 11.1111% | 13.6364% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MNPR
2026-04-08 04:09:28
JonesTrading analyst Soumit Roy maintained a Buy rating on Monopar Therapeutics Inc (MNPR) with a $130 price target, highlighting insights on the Healthcare sector. This follows a previous Buy rating from Lake Street's Chad Messer, although TipRanks-xAI reiterated a Hold rating. The company reported a reduced quarterly GAAP net loss of $5.2 million for the quarter ending December 31.
2026-04-06 05:40:06
This article provides an overview of Monopar Therapeutics Inc. (1IY0.SG), including its stock price, news, quotes, and historical data. As of April 10, the stock was trading at 47.20 EUR, down 3.48%. The company has shown strong performance over the past year and three years, significantly outperforming the S&P 500.
2026-04-05 02:39:58
This article provides recent news and events related to Monopar Therapeutics (MNPR). Key updates include the company's Q4 earnings miss and 2025 financial results, the appointment of an Chief Commercial and Strategy Officer to prepare for an NDA submission in H1 2026, and exceeding EPS consensus estimates in a previous quarter. The company also announced sufficient funds to continue operations through December 2027 to advance its drug candidates.
2026-04-04 03:10:20
This Yahoo Finance page provides a comprehensive overview of Monopar Therapeutics Inc. (1IY0.SG), including its current stock price, recent news articles, and performance data. The company's stock is trading at 47.40 EUR with a slight increase. News headlines suggest analyst interest, potential discounts, and institutional investor activity, while performance metrics show significant long-term gains.
2026-04-03 02:10:20
This Yahoo Finance page provides the latest press releases and corporate news for Monopar Therapeutics Inc. (1IY0.SG), including financial results, leadership appointments, and data presentations for their drug candidates. It also offers financial data such as price performance and links to detailed company information.
2026-04-02 19:09:19
Monopar Therapeutics COO Andrew Cittadine increased his direct equity holdings through the vesting of 3,514 restricted stock units (RSUs) on March 31, 2026. While 1,571 shares were withheld to cover tax obligations, no open-market sale occurred, and Cittadine now directly owns 52,669 shares of Monopar common stock. This transaction is considered a neutral impact event in insider trading.
